Bioventix Plc Trading Update & Notice of Results

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                      Trading Update & Notice of Results 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, is pleased to announce a trading update for the year 
ended 30 June 2022 ("FY2022"). 
 
As announced in our interim results to 31 December 2021, we had a slow start to 
the financial year. However, in the second half, we have seen an improvement in 
performance and our trading result for FY2022 as a whole is likely to be 
significantly ahead of market expectations. 
 
This improvement reflects a degree of recovery from the pandemic effects 
experienced since early 2020, and we hope that this recovery will prove to be 
sustained and long-lasting. We are pleased that the roll-out of high 
sensitivity troponin products, that are supported by our technology, has also 
matched our expectations. 
 
In addition, our results are reported in UK Sterling and the recent fall in 
value of the UK Sterling against the US Dollar has had a positive effect. 
Approximately 50% of our revenues are linked to US Dollars and royalties 
received recently from customers in respect of our H2 sales have been converted 
at more favourable exchange rates. 
 
Notice of Results 
 
Bioventix expects to release FY2022 results on 24 October 2022. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law 
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed 
in accordance with the company's obligations under Article 17 of MAR. 
 
 
 
END

(END) Dow Jones Newswires

September 14, 2022 02:00 ET (06:00 GMT)

Bioventix (AQSE:BVXP.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024